Published on Roswell Park Cancer Institute (http://www.roswellpark.org)

Vice Chair and Chief of Gastrointestinal Surgery
Professor of Oncology
Department of Surgical Oncology
Roswell Park Cancer Institute
Profile
Areas of Expertise: 
Colorectal cancer
Esophageal cancer
Liver cancer
Pancreatic cancer
Small intestine cancer
Stomach cancer
Research
Research Interests: 
Design, synthesis and evaluation of novel selective inhibitors of FAK and IGF-1R function in cancer.
Targeted, image guided release of combinatorial FAK inhibitors in pancreatic cancer.
Novel agents that target FAK and IGF-1R protein interactions.
FAK and IGF-1R interactions in pancreatic cancer survival.
Nanoparticle directed therapy for GI malignancy.
Technical advances in minimally invasive esophagectomy and minimally invasive gastr.ectomy
Outcomes for patients undergoing surgical therapy for upper gastrointestinal cancers.
Background Information
Education and Training: 
MD, New York University School of Medicine
Residency: 
1996-1997: Executive Chief Resident: New York University Medical Center, Department of Surgery
1991-1996: Resident, New York University Medical Center, Categorical General Surgery Housestaff in Department of Surgery
Board Certification: 
1998: American Board of Surgery, recertification: 2008
Fellowships: 
1997-1999: Memorial Sloan-Kettering Cancer Center, Department of Surgery
1993-1995: Memorial Sloan-Kettering Cancer Center, Surgical Metabolism Laboratory, under Michael Burt, M.D., Ph.D., and Murray F. Brennan, M.D.
Honors and Awards: 
1981 Finalist, National Westinghouse Science Competition
1985 Alpha Epsilon Delta Premedical Honor Society: Johns Hopkins University
1993-5: NCI National Research Service Award
1996 New York University Housestaff award for scholarship
1997 SSAT / Ross Laboratory presentation
1999 SSAT / Ross Laboratory presentation
2001 University of Florida Lester Dragstedt Physician-Scientist Award
2002 University of Florida Lester Dragstedt Physician-Scientist Award
2005 University of Florida, Dept. of Surgery Research Career Development Award
2005-2007, 2009, 2011 Best Doctors in America
2007 Commission on Cancer: Cancer Liaison Physician Outstanding Performance Award
2008 The Edward M. Copeland Professor of Surgical Oncology at University of Florida
2008 Florida State Chair, Commission on Cancer
Publications
Publications: 
  • Zheng D, Golubovskaya V, Kurenova E, Wood C, Massoll NA, Ostrov D, Cance WG, Hochwald SN. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Molecular carcinogenesis 2010; 49(2):200-209
  • Beasley GM, Ross MI, Pruitt SK, Seigler H, Kane JM, Noyes RD, Andtbacka RH, Delman KA, Grobmyer SR, Hochwald SN, Zager JS, Mosca PJ, Padussis J, McMahon NS, Petersen RP, Caudle A, Tyler DS. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. Journal of the American College of Surgeons 2009; 208(5):706-715; discussion 715-7
  • Hochwald SN, Cance WG, Ostrov D, Magis A, Massoll NA, Wood C, Zheng D, Zheng M, Nyberg C, Golubovskaya VM. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell cycle (Georgetown, Tex.) 2009; 8(15):2435-2443
  • Santillan AA, Tyler DS, Ross MI, Kane JM, Noyes RD, Andtbacka RH, Grobmyer SR, Hochwald SN, Mosca PJ, Beasley GM, Delman KA, Zager JS. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Annals of surgical oncology 2009; 16(9):2570-2578
  • Zheng D, Kurenova E, Ucar D, Golubovskaya V, Magis A, Ostrov D, Cance WG, Hochwald SN. Targeting of the protein interaction site between FAK and IGF-1R. Biochemical and biophysical research communications 2009; 388(2):301-305
  • Ucar DA, Cox A, He D-H, Ostrov DA, Kurenova E, Hochwald SN. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma. Anti-cancer agents in medicinal chemistry 2011; 11(7):629-637
  • Kurenova EV, Liao J, He D, Hunt DL, Chekhau A, Hochwald SN, Ostrov DA, Cance WG. Effect of a novel FAK inhibitor targeted to the binding site of VEGFR3 on pancreatic cancer proliferation in vitro and in vivo : 2011 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2011; 29(4 Suppl.):214
  • Grobmyer SR, Cance WG, Copeland EM, Vogel SB, Hochwald SN. Is there an indication for initial conservative management of pancreatic cystic lesions? . Journal of surgical oncology 2009; 100(5):372-374
  • Grobmyer SR, Hemming AW, Harris N, Behrns K, Logan H, Kim RD, Chang M, Cance WG, Hochwald SN. A pilot prospective randomized trial of postoperative epoetin alfa in patients undergoing major operation for upper gastrointestinal malignancy. American journal of clinical oncology 2009; 32(6):570-573
  • Grobmyer SR, Mortellaro VE, Moore Higgs G, Hochwald SN, Mendenhall NP, Copeland III EM, Cance WG. Is there a role for routine use of MRI in selection of patients for breast-conserving cancer therapy? . Journal of the American College of Surgeons 2008; 206(5):1045-1050; discussion 1050-1052
  • Hochwald SN, Golubovskaya VM. FAK as a target for cancer therapy. Gene therapy and molecular biology 2009; 13(1):26-35
  • Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29(6):1096-1107
  • Waterman AL, Grobmyer SR, Cance WG, Hochwald SN. Is endoscopic resection of gastric gastrointestinal stromal tumors safe? . American surgeon 2008; 74(12):1186-1189
  • Shaw CM, Grobmyer SR, Deniza U, Cance WG, Reith JD, Hochwald SN. Elevated expression of IRS2 in the progression from neurofibroma to malignant peripheral nerve sheath tumor. Anticancer research 2012; 32(2):439-443
  • Ucar DA, Cox A, He D-H, Patel R, Kurenova E, Hochwald SN. A novel therapeutic strategy for malignancy: Specific disruption of FAK and IGF-1R interaction with a small molecule compound . Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:Abstract #2538
  • Ben-David K, Ang D, Grobmyer SR, Liu H, Kim T, Hochwald SN. Esophagectomy in the state of Florida: is regionalization of care warranted?. American surgeon 2012; 78(3):291-295
  • Ben-David K, Sarosi GA, Cendan JC, Howard D, Rossidis G, Hochwald SN. Decreasing morbidity and mortality in 100 consecutive minimally invasive esophagectomies. Surgical endoscopy 2012; 26(1):162-167
  • Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD, Hollingshead M, Hunter KW, Kaye FJ, Hochwald SN, Marquez VE, Steeg P, Zajac-Kaye M. DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. Molecular cancer therapeutics 2012; 11(2):370-382
  • Gu Y, Lin S, Li JL, Nakagawa H, Chen Z, Jin B, Tian L, Ucar DA, Shen H, Lu J, Hochwald SN, Kaye FJ, Wu L. Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene 2012; 31(4):469-479
  • Paryani NN, Zlotecki RA, Swanson EL, Morris CG, Grobmyer SR, Hochwald SN, Marcus RB Jr, Indelicato DJ. Multimodality local therapy for retroperitoneal sarcoma. International journal of radiation oncology, biology, physics 2012; 82(3):1128-1134
  • Rossidis G, Arroyo MR, Abbitt PL, Grobmyer SR, Hochwald SN. Malignant transformation of a pancreatic serous cystadenoma. American surgeon 2012; 78(2):260-263
  • Chai CY, Deneve JL, Beasley GM, Marzban SS, Chen YA, Rawal B, Grobmyer SR, Hochwald SN, Tyler DS, Zager JS. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Annals of surgical oncology 2012; 19(5):1637-1643
  • Grobmyer SR, Gutwein LG, Ang DN, Marshall JK, Copeland EM, Hochwald SN. Re:"percutaneous needle vs surgical breast biopsy: previous allegations of overuse of surgery are in error". Journal of the American College of Radiology : JACR 2012; 9(5):373-374; author reply 374-375
  • Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, Zajac-Kaye M, Hochwald SN. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell cycle (Georgetown, Tex.) 2012; 11(17):3250-3259
Referral
Email: 
Steven.Hochwald@RoswellPark.org
Fax: 
716-845-1668
Source URL (retrieved on 06/20/2013 - 1:33am): http://www.roswellpark.org/steven-hochwald